John M. Maris

53.4k total citations · 7 hit papers
472 papers, 26.5k citations indexed

About

John M. Maris is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, John M. Maris has authored 472 papers receiving a total of 26.5k indexed citations (citations by other indexed papers that have themselves been cited), including 338 papers in Neurology, 235 papers in Molecular Biology and 144 papers in Cancer Research. Recurrent topics in John M. Maris's work include Neuroblastoma Research and Treatments (333 papers), Cancer, Hypoxia, and Metabolism (123 papers) and Cancer therapeutics and mechanisms (89 papers). John M. Maris is often cited by papers focused on Neuroblastoma Research and Treatments (333 papers), Cancer, Hypoxia, and Metabolism (123 papers) and Cancer therapeutics and mechanisms (89 papers). John M. Maris collaborates with scholars based in United States, Australia and Canada. John M. Maris's co-authors include Susan L. Cohn, Katherine K. Matthay, Michael D. Hogarty, Rochelle Bagatell, C. Patrick Reynolds, Wendy B. London, Malcolm A. Smith, Yaël P. Mossé, Robert C. Seeger and Garrett M. Brodeur and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

John M. Maris

455 papers receiving 26.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neuroblastoma

2007 1.6k citations John M. Maris, Rochelle Bagatell et al. profile →
Recent Advances in Neuroblastoma

2010 1.4k citations John M. Maris profile →
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

2010 1.2k citations Alice L. Yu, Andrew L. Gilman et al. profile →
Neuroblastoma

2016 897 citations Katherine K. Matthay, John M. Maris et al. profile →
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

2013 477 citations Yaël P. Mossé, Stephan D. Voss et al. profile →
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

2021 249 citations Arlene Naranjo, Susan L. Cohn et al. profile →
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

2019 214 citations Julie R. Park, Wendy B. London et al. profile →

Peers

John M. Maris

NEURO

ONCOL

PRM

Garrett M. Brodeur United States

Robert C. Seeger United States

C. Patrick Reynolds United States

Akira Nakagawara Japan

Aldo Scarpa Italy

Cynthia Hawkins Canada

Warren Mason Canada

Henry S. Friedman United States

Peter C. Burger United States

Julian Downward United Kingdom

Garrett M. Brodeur United States

John M. Maris

16.2k ×1.0

NEURO

14.4k ×1.1

6.6k ×0.8

5.2k ×0.8

ONCOL

1.5k ×0.6

PRM

Citations per year, relative to John M. Maris John M. Maris (= 1×) peers Garrett M. Brodeur

Countries citing papers authored by John M. Maris

Since Specialization

Citations

This map shows the geographic impact of John M. Maris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Maris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Maris more than expected).

Fields of papers citing papers by John M. Maris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Maris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Maris. The network helps show where John M. Maris may publish in the future.

Co-authorship network of co-authors of John M. Maris

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Maris. A scholar is included among the top collaborators of John M. Maris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Maris. John M. Maris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Yi, S. K. Gupta, Samuel E. Garfinkle, et al.. (2023). Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion. Science Immunology. 8(90). eadj5792–eadj5792. 10 indexed citations

Foster, Jessica, Jo Lynne Rokita, Komal S. Rathi, et al.. (2022). Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. Journal for ImmunoTherapy of Cancer. 10(9). e004450–e004450. 30 indexed citations

Batra, Vandana, Minu Samanta, Mehran Makvandi, et al.. (2022). Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma. Clinical Cancer Research. 28(18). 4146–4157. 18 indexed citations

Yu, Alice L., Andrew L. Gilman, M. Fevzi Özkaynak, et al.. (2021). Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research. 27(8). 2179–2189. 132 indexed citations

Makvandi, Mehran, Hwan Lee, Laura N. Puentes, et al.. (2019). Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. Molecular Cancer Therapeutics. 18(7). 1195–1204. 39 indexed citations

Cole, Kristina A., Sharmistha Pal, Rachel A. Kudgus, et al.. (2019). Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research. 26(6). 1213–1219. 48 indexed citations

Wei, Jun S., Igor B. Kuznetsov, Shile Zhang, et al.. (2018). Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN -Not-Amplified Human Neuroblastoma. Clinical Cancer Research. 24(22). 5673–5684. 76 indexed citations

Deveau, Paul, Léo Colmet‐Daage, Derek A. Oldridge, et al.. (2018). QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics. 34(11). 1808–1816. 18 indexed citations

Hart, Lori S., JulieAnn Rader, Pichai Raman, et al.. (2016). Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clinical Cancer Research. 23(7). 1785–1796. 57 indexed citations

10.

Murphy, Brendan, John M. Maris, E. Anders Kolb, et al.. (2016). Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Research. 76(19). 5798–5809. 40 indexed citations

11.

Russell, Mike R., Derek A. Oldridge, Juan R. Alvarez‐Dominguez, et al.. (2015). CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Research. 75(15). 3155–3166. 120 indexed citations

12.

Rader, JulieAnn, Mike R. Russell, Lori S. Hart, et al.. (2013). Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clinical Cancer Research. 19(22). 6173–6182. 308 indexed citations

13.

García, Idoia, José Ríos, Gema Doménech, et al.. (2012). A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research. 18(7). 2012–2023. 51 indexed citations

14.

Russell, Mike R., JulieAnn Rader, Lili T. Belcastro, et al.. (2012). Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma. Cancer Research. 73(2). 776–784. 95 indexed citations

15.

Balamuth, Naomi, Andrew Wood, Qun Wang, et al.. (2010). Serial Transcriptome Analysis and Cross-Species Integration Identifies Centromere-Associated Protein E as a Novel Neuroblastoma Target. Cancer Research. 70(7). 2749–2758. 41 indexed citations

16.

Qing, Guoliang, Nicolas Skuli, Patrick A. Mayes, et al.. (2010). Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α. Cancer Research. 70(24). 10351–10361. 128 indexed citations

17.

Houghton, Peter J., Christopher L. Morton, Richard Görlick, et al.. (2010). Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics. 9(1). 101–112. 79 indexed citations

18.

Preter, Katleen De, Joëlle Vermeulen, Benedikt Brors, et al.. (2010). Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research. 16(5). 1532–1541. 65 indexed citations

19.

Volchenboum, Samuel L., Cheng Li, Shuli Li, et al.. (2009). Comparison of Primary Neuroblastoma Tumors and Derivative Early-Passage Cell Lines Using Genome-Wide Single Nucleotide Polymorphism Array Analysis. Cancer Research. 69(10). 4143–4149. 21 indexed citations

20.

Cole, Kristina A., Edward F. Attiyeh, Yaël P. Mossé, et al.. (2008). A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene. Molecular Cancer Research. 6(5). 735–742. 242 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact